July 15, 2025

Supplementary Data S4 from Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Trend analysis reveals initial favorable response to decitabine in TP53-mutated MDS/AML, suggesting relapse mechanisms.

Main finding shows a favorable response to decitabine in patients with TP53 mutations in MDS/AML.
Key evidence indicates trends in treatment response may help understand relapse occurrences.
Approach involved analyzing supplementary data to track trends in treatment response.
Significance lies in revealing mechanisms that could help improve treatment strategies for MDS/AML patients.

Ng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark